CompanyGraph
At a glance
- Depends onMidstream position: 6 outgoing, 8 incoming connections
- ScaleMarket cap is $1.87B, above the global median of $1.15B
- PositionReturn on equity is 17.2%, higher than 95% of its Medical Devices peers (median 3%)
- Interpretations7 currently firing — 7
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
1.87BUSDvs all stocks (USD)
Trailing P/E
27.57xvs Medical Devices peers
Revenue (TTM)
608.85MUSDvs all stocks (USD)
Profit Margin
11.27%vs Medical Devices peers
Beta
1.07xvs all stocks
52-Week Change
6.71%vs all stocks
Market Capitalization
1.87BUSDvs all stocks (USD)
Enterprise Value
2.01BUSDvs all stocks (USD)
Trailing P/E
27.57xvs Medical Devices peers
Forward P/E
20.71xvs Medical Devices peers
PEG Ratio
20.58xvs Medical Devices peers
Price to Sales (TTM)
3.08xvs Medical Devices peers
Price to Book (MRQ)
4.27xvs Medical Devices peers
Enterprise to Revenue
3.30xvs Medical Devices peers
Enterprise to EBITDA
17.88xvs Medical Devices peers
Gross Margin
28.77%vs Medical Devices peers
Profit Margin
11.27%vs Medical Devices peers
Operating Margin
15.14%vs Medical Devices peers
Return on Assets (TTM)
8.81%vs Medical Devices peers
Return on Equity (TTM)
17.17%vs Medical Devices peers
Revenue (TTM)
608.85MUSDvs all stocks (USD)
Revenue per Share (TTM)
78.94USDUpdated Jul 19, 2026Quarterly Revenue Growth
4.10%vs Medical Devices peers
Gross Profit (TTM)
172.62MUSDvs all stocks (USD)
EBITDA (TTM)
112.29MUSDvs all stocks (USD)
Net Income (TTM)
68.62MUSDvs all stocks (USD)
Quarterly Earnings Growth (YoY)
1.80%vs Medical Devices peers
Operating Cash Flow (TTM)
81.30MUSDvs all stocks (USD)
Levered Free Cash Flow (TTM)
53.57MUSDvs all stocks (USD)
Trailing Annual Dividend Rate
0.00USDUpdated Jul 19, 2026Trailing Annual Dividend Yield
0.00%vs all stocks
Payout Ratio
0.00%vs Medical Devices peers
Revenue
602.80MUSDFY2025 · Dec 31, 2025Cost of Goods Sold
432.39MUSDFY2025 · Dec 31, 2025Gross Profit
170.41MUSDFY2025 · Dec 31, 2025Operating Income
92.97MUSDvs all stocks (USD)
Pre-tax Income
82.51MUSDFY2025 · Dec 31, 2025Income Tax Expense
14.20MUSDFY2025 · Dec 31, 2025Net Income
68.31MUSDFY2025 · Dec 31, 2025EBIT
92.32MUSDFY2025 · Dec 31, 2025EBITDA (Income Statement)
112.10MUSDFY2025 · Dec 31, 2025Selling, General & Administrative
77.44MUSDFY2025 · Dec 31, 2025Non-operating Interest Expense
9.80MUSDFY2025 · Dec 31, 2025EPS (Basic)
8.87USDFY2025 · Dec 31, 2025EPS (Diluted)
8.75USDFY2025 · Dec 31, 2025Basic Shares Outstanding
7.71MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
7.71MSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
68.31MUSDFY2025 · Dec 31, 2025Operating Cash Flow
96.45MUSDFY2025 · Dec 31, 2025Free Cash Flow
83.57MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
20.30MUSDFY2025 · Dec 31, 2025Income Tax Paid
2.78MUSDFY2025 · Dec 31, 2025Interest Paid
9.86MUSDFY2025 · Dec 31, 2025Starting Profit (CF Statement)
68.31MUSDFY2025 · Dec 31, 2025Depreciation & Amortization
19.15MUSDFY2025 · Dec 31, 2025Deferred Taxes (CF)
5.11MUSDFY2025 · Dec 31, 2025Stock-based Compensation
8.85MUSDFY2025 · Dec 31, 2025Other Non-cash Items
261.00KUSDFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
4.79MUSDFY2025 · Dec 31, 2025Change in Accounts Payable (CF)
-1.09MUSDFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-8.94MUSDFY2025 · Dec 31, 2025Capital Expenditures
-12.88MUSDFY2025 · Dec 31, 2025Net Acquisitions
-14.72MUSDFY2025 · Dec 31, 2025Net Investing Cash Flow
-27.60MUSDFY2025 · Dec 31, 2025Long-term Debt Issuance
68.70MUSDFY2025 · Dec 31, 2025Long-term Debt Payments
-122.68MUSDFY2025 · Dec 31, 2025Other Financing Charges
-4.37MUSDFY2025 · Dec 31, 2025Net Financing Cash Flow
-58.35MUSDFY2025 · Dec 31, 2025Shares Outstanding
7.74MSharesUpdated Jul 19, 2026Float Shares
7.43MSharesUpdated Jul 19, 2026Shares Short
1.34MSharesUpdated Jul 19, 2026Short Ratio
6.50daysvs all stocks
Short % of Shares Outstanding
24.01%vs all stocks
% Held by Insiders
4.04%vs all stocks
% Held by Institutions
120.82%vs all stocks
Total Cash (MRQ)
19.98MUSDvs all stocks (USD)
Total Cash per Share (MRQ)
2.58USDUpdated Jul 19, 2026Total Debt (MRQ)
156.07MUSDvs all stocks (USD)
Total Debt to Equity (MRQ)
0.3556xvs Medical Devices peers
Current Ratio (MRQ)
2.91xvs Medical Devices peers
Book Value per Share (MRQ)
56.73USDUpdated Jul 19, 2026Total Assets
655.08MUSDvs all stocks (USD)
Total Current Assets
201.00MUSDFY2025 · Dec 31, 2025Total Liabilities
231.20MUSDFY2025 · Dec 31, 2025Total Non-current Assets
454.08MUSDFY2025 · Dec 31, 2025Total Non-current Liabilities
156.34MUSDFY2025 · Dec 31, 2025Total Current Liabilities
74.86MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents
20.30MUSDFY2025 · Dec 31, 2025Accounts Receivable
82.91MUSDFY2025 · Dec 31, 2025Inventory
86.86MUSDFY2025 · Dec 31, 2025Accounts Payable
24.29MUSDFY2025 · Dec 31, 2025Short-term Debt
17.54MUSDFY2025 · Dec 31, 2025Deferred Revenue
4.24MUSDFY2025 · Dec 31, 2025Long-term Debt
136.94MUSDFY2025 · Dec 31, 2025Other Non-current Liabilities
3.52MUSDFY2025 · Dec 31, 2025Common Stock (Book)
77.00KUSDFY2025 · Dec 31, 2025Retained Earnings
374.81MUSDFY2025 · Dec 31, 2025Total Shareholders' Equity
423.88MUSDvs all stocks (USD)
Treasury Stock
587.00KUSDFY2025 · Dec 31, 202552-Week Low
173.86USDUpdated Jul 19, 202652-Week High
279.49USDUpdated Jul 19, 202652-Week Change
6.71%vs all stocks
Beta
1.07xvs all stocks
50-Day MA
235.24USDUpdated Jul 19, 2026200-Day MA
222.66USDUpdated Jul 19, 2026Avg 10-Day Volume
245.61KSharesUpdated Jul 19, 2026Avg 30-Day Volume
220.22KSharesUpdated Jul 19, 2026Diluted EPS (TTM)
8.78USDUpdated Jul 19, 2026Other Income / Expense
-654.00KUSDFY2025 · Dec 31, 20257 interpretations currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsHow does this company use capital?
FCF Ratios Elevated
Its free cash flow is large next to assets and equity, and more of its operating cash reaches it than in its industry.
Reads
Industry-Benchmarked Return on Capital Elevated
It earns more on its assets and its equity than its industry, and gets more sales from those assets.
Reads
Low Fixed-Asset Share With Elevated Turnover
It owns few buildings and machines, yet gets more sales and profit from its assets than its industry does.
Reads
Operating Income Growing With Multi-Year Revenue Growth
Revenue up in each of five years, with operating income up in each of four.
Reads
Multi-Year FCF With Growth And Margin
Three years of positive free cash flow and rising revenue, four of rising equity, and much of its sales turns into cash.
Reads
ROE, ROA, And Operating ROA Elevated
It earns more on its equity than its industry does, and on its assets too — not on borrowing alone.
Reads
Is this company growing?
Multi-Year Revenue, Profit, And Income Growth
Revenue has risen in each of three years, gross profit in each of four, and it has made a profit in all five.
Reads
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Peer Positioning
Return on equity is 17.2%, higher than 95% of its Medical Devices peers (median 3%)Significant
Return on equity: 0.17Industry median: 0.03Industry P95: 0.17Peers compared: 102
Financial Health
Altman Z-Score 7.28: safe zoneNotable
Altman Z-Score: 7.28
Supply Chain
Midstream position: 6 outgoing, 8 incoming connectionsNotable
Outgoing: 6.00Incoming: 8.00
High connectivity hub: 14 industry connectionsNotable
Total Connections: 14.00
Scale
Market cap is $1.87B, above the global median of $1.15BNotable
Market cap (USD): 1,872,726,108Global Median: 1,146,734,693.424
Revenue is $608.85M, above the global median of $520.53MNotable
Revenue (USD): 608,851,008Global Median: 520,528,949.311
Levered free cash flow is $53.57M, above the global median of $16.24MNotable
Levered free cash flow (USD): 53,567,248Global Median: 16,239,329.704
Companies that share the same coordination system — how they create, deliver, or capture value.
Nanjing Vazyme Biotech Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
AbCellera Biologics Inc.
Tier 1ProductionApproval-Gated PipelineRuleSenseMaking
Zenas BioPharma, Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Jafron Biomedical Co. Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Yifan Pharmaceutical Co. Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Guobang Pharma Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Hugel Inc.
Tier 1ProductionApproval-Gated PipelineRule
Amylyx Pharmaceuticals, Inc. Common Stock
Tier 1ProductionApproval-Gated PipelineRule
Hunan Jingfeng Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Companies that share active interpretations — structural patterns currently present in both stocks.
Nextracker Inc.
7 interpretationsFCF Ratios ElevatedROE, ROA, And Operating ROA ElevatedOperating Income Growing With Multi-Year Revenue GrowthMulti-Year Revenue, Profit, And Income GrowthIndustry-Benchmarked Return on Capital ElevatedLow Fixed-Asset Share With Elevated TurnoverMulti-Year FCF With Growth And Margin
XPEL, Inc.
6 interpretationsFCF Ratios ElevatedROE, ROA, And Operating ROA ElevatedMulti-Year Revenue, Profit, And Income GrowthIndustry-Benchmarked Return on Capital ElevatedLow Fixed-Asset Share With Elevated TurnoverMulti-Year FCF With Growth And Margin
NVIDIA Corporation
7 interpretationsFCF Ratios ElevatedROE, ROA, And Operating ROA ElevatedOperating Income Growing With Multi-Year Revenue GrowthMulti-Year Revenue, Profit, And Income GrowthIndustry-Benchmarked Return on Capital ElevatedLow Fixed-Asset Share With Elevated TurnoverMulti-Year FCF With Growth And Margin